arrow
I

Ioannis Gounaris

merck kga a
H指数:21
被引数:3,788

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

An Integrated Nonclinical and Clinical Risk Assessment of the Effects of Investigational ATRi Tuvusertib on QTc Interval in Patients With Solid Tumors

ATR抑制剂Tuvusertib对实体瘤患者QTc间期影响的综合非临床与临床风险评估

2026-02-100
OAAI
A phase II, multicenter, open-label, single-arm study of berzosertib plus topotecan in patients with relapsed platinum-resistant small-cell lung cancer (DDRiver SCLC 250)

II期、多中心、开放标签、单臂研究:伯佐塞替联合拓扑替康治疗复发铂耐药小细胞肺癌患者(DDRiver SCLC 250)

2025-12-010
OAAI
Integrated Population Pharmacokinetic, Pharmacodynamic, and Safety Analyses to Inform Dosage Selection in the Clinical Development of the ATR Inhibitor Tuvusertib

整合群体药代动力学、药效动力学和安全性的综合分析,以指导ATR抑制剂Tuvusertib在临床开发中的剂量选择

2025-08-210
OAAI
Paediatric Strategy Forum for medicinal product development of DNA damage response pathway inhibitors in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration
2023-09-016
OAAI
6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial

6个月与12个月曲妥珠单抗辅助治疗HER2-positive早期乳腺癌 (PERSEPHONE): 一项随机3期非劣效性试验的4年无病生存率结果

LANCET
IF88.5
2019-06-01224
OAAI
Enhanced detection of circulating tumor DNA by fragment size analysis
2018-11-07671
OAAI
Central pathology review with two-stage quality assurance for pathological response after neoadjuvant chemotherapy in the ARTemis Trial
2017-08-0113
OAAI
Disease-free and overall survival at 3.5 years for neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide, for women with HER2 negative early breast cancer: ARTemis Trial
2017-08-0133
OAAI